Armistice Capital Master Fund Ltd.
CIK 1633584 · last filed 2022-02-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VXRT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
510 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVTX | Director | 16,393 | $6.73 | $110.3K | $335.4K | 1 | 2022-02-28 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Director | 39,712,442 | $2.93 | $116.36M | $24.90M | 19 | 2021-08-18 |
| EYEG | Director | 2,576,500 | $33.78 | $87.05M | -$39.51M | 5 | 2021-08-03 |
| AYTU | Director | 134,238 | $1.94 | $260.4K | -$121.50M | 8 | 2021-05-10 |
| TENX | Director | 2,449 | $1.65 | $4.0K | $369.7K | 1 | 2020-09-03 |
| Vaxart, Inc. (VXRT) Delisted | Director | 14,970,909 | $0.32 | $4.79M | -$898.30M | 5 | 2020-06-30 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | 10%+ Owner | 4,400,000 | — | — | $2.60M | 1 | 2020-01-28 |
| ACHV | 10%+ Owner | 95,599 | $6.68 | $638.6K | -$2.37M | 1 | 2019-06-13 |
| Del Frisco's Restaurant Group, Inc. (DFRG) Delisted | 10%+ Owner | 6,000,000 | — | — | $12.02M | 4 | 2019-04-30 |
| Valeritas Holdings Inc. (VLRX) Delisted | 10%+ Owner | 1,972,500 | — | — | $845.8K | 3 | 2018-12-20 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | 10%+ Owner | 35,025,915 | — | — | $3.38M | 13 | 2018-10-09 |
| Fresh Tracks Therapeutics, Inc. (VICL) Delisted | 10%+ Owner | 1,222,757 | — | — | $7.58M | 4 | 2018-07-02 |
Recent Filings · Page 7 of 8
74 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-27 | Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Buy (P) | +155,415 | $192.4K | EDGAR |
| 2018-06-13 | Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Buy (P) | +2,012,691 | $2.34M | EDGAR |
| 2018-05-23 | Avalo Therapeutics, Inc. (CERCW) Delisted | Buy (P) | +150,000 | $567.5K | EDGAR |
| 2018-05-11 | EYEG | Buy (P) | +531,036 | $273.0K | EDGAR |
| 2018-04-18 | Avalo Therapeutics, Inc. (CERCW) Delisted | Buy (P) | +450,000 | $1.54M | EDGAR |
| 2018-01-26 | Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Buy (P) | +300,000 | $429.1K | EDGAR |
| 2017-10-18 | Avalo Therapeutics, Inc. (CERCW) Delisted | Buy (P) | +14,400 | $15.5K | EDGAR |
| 2017-10-03 | Avalo Therapeutics, Inc. (CERCW) Delisted | Buy (P) | +20,649 | $18.0K | EDGAR |
| 2017-09-28 | Avalo Therapeutics, Inc. (CERCW) Delisted | Buy (P) | +41,856 | $33.3K | EDGAR |
| 2017-09-25 | Avalo Therapeutics, Inc. (CERCW) Delisted | Buy (P) | +43,980 | $34.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.